Phio Pharmaceuticals Corp. announced its third quarter 2025 financial results and provided a business update. The company reported progress in its Phase 1b clinical trial of INTASYL PH-762 for skin cancer, advancing to the fifth and final cohort at the maximum dose. At this dose, one patient achieved 100% tumor clearance (complete response), a second patient had greater than 90% tumor clearance (near complete response), and a third patient showed greater than 50% tumor clearance (partial response). No dose-limiting toxicities or clinically relevant treatment-emergent adverse effects were observed, and PH-762 was well tolerated across all dose cohorts. The Safety Monitoring Committee issued a favorable review of safety data at the maximum dose. In addition, Phio completed a warrant inducement financing in November 2025, securing expected net proceeds of approximately $12.1 million, extending the company's cash runway into the first half of 2027. The company also highlighted recent scientific and investor presentations related to its INTASYL siRNA technology and ongoing clinical developments.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phio Pharmaceuticals Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 274265) on November 13, 2025, and is solely responsible for the information contained therein.
Comments